title: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease.
abstract: BACKGROUND
  It is controversial whether prolonged antibiotic treatment is effective for patients in whom symptoms persist after the recommended antibiotic treatment for acute Lyme disease.
  
  
  METHODS
  We conducted two randomized trials: one in 78 patients who were seropositive for IgG antibodies to Borrelia burgdorferi at the time of enrollment and the other in 51 patients who were seronegative. The patients received either intravenous ceftriaxone, 2 g daily for 30 days, followed by oral doxycycline, 200 mg daily for 60 days, or matching intravenous and oral placebos. Each patient had well-documented, previously treated Lyme disease but had persistent musculoskeletal pain, neurocognitive symptoms, or dysesthesia, often associated with fatigue. The primary outcome measures were improvement on the physical- and mental-health-component summary scales of the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36)--a scale measuring the health-related quality of life--on day 180 of the study.
  
  
  RESULTS
  After a planned interim analysis, the data and safety monitoring board recommended that the studies be discontinued because data from the first 107 patients indicated that it was highly unlikely that a significant difference in treatment efficacy between the groups would be observed with the planned full enrollment of 260 patients. Base-line assessments documented severe impairment in the patients' health-related quality of life. In intention-to-treat analyses, there were no significant differences in the outcomes with prolonged antibiotic treatment as compared with placebo. Among the seropositive patients who were treated with antibiotics, there was improvement in the score on the physical-component summary scale of the SF-36, the mental-component summary scale, or both in 37 percent, no change in 29 percent, and worsening in 34 percent; among seropositive patients receiving placebo, there was improvement in 40 percent, no change in 26 percent, and worsening in 34 percent (P=0.96 for the comparison between treatment groups). The results were similar for the seronegative patients.
  
  
  CONCLUSIONS
  There is considerable impairment of health-related quality of life among patients with persistent symptoms despite previous antibiotic treatment for acute Lyme disease. However, in these two trials, treatment with intravenous and oral antibiotics for 90 days did not improve symptoms more than placebo.
authors.affiliation: New England Medical Center and Tufts University School of Medicine, Boston, MA, USA. klempner@bu.edu
authors.forename: M S
authors.initials: MS
authors.lastname: Klempner
authors.forename: L T
authors.initials: LT
authors.lastname: Hu
authors.forename: J
authors.initials: J
authors.lastname: Evans
authors.forename: C H
authors.initials: CH
authors.lastname: Schmid
authors.forename: G M
authors.initials: GM
authors.lastname: Johnson
authors.forename: R P
authors.initials: RP
authors.lastname: Trevino
authors.forename: D
authors.initials: D
authors.lastname: Norton
authors.forename: L
authors.initials: L
authors.lastname: Levy
authors.forename: D
authors.initials: D
authors.lastname: Wall
authors.forename: J
authors.initials: J
authors.lastname: McCall
authors.forename: M
authors.initials: M
authors.lastname: Kosinski
authors.forename: A
authors.initials: A
authors.lastname: Weinstein
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood; D015748:Borrelia burgdorferi Group / Q000276:immunology; D002443:Ceftriaxone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D004318:Doxycycline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008193:Lyme Disease / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D002443:Ceftriaxone; D004318:Doxycycline